Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Allarity Therapeutics, Inc. - Common stock
(NQ:
ALLR
)
0.9538
+0.0400 (+4.38%)
Delayed Quote
Updated: 4:00 PM EST, Nov 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allarity Therapeutics, Inc. - Common stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
34 Stocks Moving In Tuesday's Mid-Day Session
↗
January 18, 2022
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares gained 37.2% to $6.75 after the company eeceived FDA Breakthrough Device Designation for the treatment of chronic chemo induced...
Via
Benzinga
Allarity, Oncoheroes Ink Agreements For Pediatric Cancer Programs
↗
January 03, 2022
Allarity Therapeutics Inc (NASDAQ: ALLR) and Oncoheroes Biosciences Inc have entered into licensing agreements for Allarity's dovitinib and stenoparib...
Via
Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
↗
December 30, 2021
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors. Future...
Via
Benzinga
63 Biggest Movers From Yesterday
↗
December 31, 2021
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
December 23, 2021
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares surged 53.4% to settle at $16.31 on Wednesday. Acasti Pharma Inc. (NASDAQ: ACST) jumped 52.3% to close at $1.69 on...
Via
Benzinga
What's Happening With Allarity Therapeutics Stock Today?
↗
December 22, 2021
Allarity Therapeutics Inc (NASDAQ: ALLR) has submitted a marketing application to the FDA seeking approval for dovitinib for the third-line treatment of renal cell...
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.